ABL-106

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameABL-106

Drug Alias NameColon cancer/renal cell carcinoma/ovarian cancer bispecific T-cell engager (ABL Bio)ABL-106

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionImmunostimulantsT lymphocytes stimulants

TargetsUpdating

Therapy Area/IndicationsOvarian NeoplasmsColonic NeoplasmsCarcinoma, Renal Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAbl Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesAbl Bio Inc

Inactive CompaniesN/A

Active IndicationsOvarian NeoplasmsColonic NeoplasmsCarcinoma, Renal Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A